Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

sting supply agreement with Boehringer Ingelheim Austria for the commercial and clinical supply of Actimmune.

Fourth Quarter and Recent Business Highlights

-- Pirfenidone: On November 26, InterMune announced that it had entered

into agreements with Marnac, Inc. and with co-licensor KDL GmbH that

will eliminate future royalty and milestone payment obligations for

pirfenidone related to the 2002 license agreement. The principal terms

of the new agreements were:

-- InterMune made total acquisition payments to the companies of $13.7

million. Of this total, a $7.5 million expense recorded in the

third quarter of 2007 relating to the 2002 license agreement was

applied to the acquisition payments for the new agreements. The

$6.2 million balance of the acquisition payments for the new

agreements was recorded in the fourth quarter of 2007.

-- Contingent acquisition payments associated with the new agreements

of up to an additional $53.5 million would be made by InterMune

only if positive Phase 3 data and registration in the United States

and European Union are achieved.

-- In addition, InterMune acquired exclusive worldwide rights from

Marnac to certain additional intellectual property for pirfenidone

that was not licensed under the 2002 licensing agreement, including

patents relating to the TNF-alpha activities of the compound.

-- ITMN-191: On January 7, 2008, InterMune reported the progress of its

Phase 1b multiple-ascending-dose (MAD) clinical trial evaluating

ITMN-191 (R7227) as monotherapy in patients with chronic hepatitis C

virus (HCV) infection. InterMune reported that:

-- It had completed the first two dosage cohorts in the study, with

total daily doses of up to 300mg, and that
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industry” is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
(Date:8/18/2014)... 18, 2014   Sterne, Kessler, Goldstein & Fox ... Washington, DC , announced today that it ... (IPR) with the U.S. Patent and Trademark Office ... BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions aim ... Myriad Genetics, Inc. These patents have been asserted against ...
(Date:8/18/2014)... , August 18, 2014 ... Bioreactor Systems Market, By Application (Municipal Wastewater Treatment ... Flat Sheet and Multi Tubular), By Configuration (Internal/Submerged ... 2019", published by MarketsandMarkets, The market for membrane ... by 2019, growing at a CAGR of 15.28% ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... cell technology to battle ... ... Bio, Inc.,announced today that John T. Dimos, Ph.D., first author of ... Can Be Differentiated into Motor Neurons," will join its team of,scientists ...
... Aug. 6 NxStage Medical, Inc.,(Nasdaq: NXTM ... announced that Jeffrey H. Burbank, Chief Executive Officer ... the following schedule,of investor conferences. Where possible, a ... http://www.nxstage.com/ir.cfm at the time of each,conference., ...
... by 11% Discovery ... Products and Services Growth -, HOPKINTON, Mass., Aug. 6 ... quarter financial,results for 2008. Revenues were $34.0 million for the quarter, ... Revenues were impacted,by a $3.5 million decline from 2007 in collaboration-related ...
Cached Biology Technology:iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits 2NxStage Announces Investor Conference Schedule 2Caliper Life Sciences Reports Second Quarter 2008 Results 2Caliper Life Sciences Reports Second Quarter 2008 Results 3Caliper Life Sciences Reports Second Quarter 2008 Results 4Caliper Life Sciences Reports Second Quarter 2008 Results 5Caliper Life Sciences Reports Second Quarter 2008 Results 6Caliper Life Sciences Reports Second Quarter 2008 Results 7Caliper Life Sciences Reports Second Quarter 2008 Results 8Caliper Life Sciences Reports Second Quarter 2008 Results 9
(Date:8/19/2014)... 2014 Smart Technology Sector improves ... as latest developments, ad campaigns and partnerships are announced: ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ), ... (NASDAQ: GOOG ) and Mastercard Incorporated (NYSE: ... authentication company focused on the growing m-commerce market releases ...
(Date:8/19/2014)... study of 9- and 10-year-olds finds that those who ... white-matter tracts in the brain than their peers who ... axons that carry nerve signals from one brain region ... faster and more efficient nerve activity. , The ... in Human Neuroscience. , "Previous studies suggest that ...
(Date:8/18/2014)... The specific composition of bacterial species in a person,s ... Campylobacter , the most common cause of human bacterial ... mBio , the online open-access journal of the American ... Campylobacter infection can yield lasting changes to one,s ... a long time that the microbiota, or microorganisms in ...
Breaking Biology News(10 mins):Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7Physically fit kids have beefier brain white matter than their less-fit peers 2Physically fit kids have beefier brain white matter than their less-fit peers 3What's in your gut? Certain bacteria may influence susceptibility to infection 2
... LOS ANGELES In research that one day may lead to ... disease, investigators at Childrens Hospital Los Angeles have identified PDGF ... epicardial cells, one type of cell that surrounds heart muscle ... September 21 in advance of the publication of the ...
... COLUMBIA, Mo. A cancer drug that benefits people ... teaching professor of oncology at the MU College of ... that examines the efficacy of Attaxol in dogs with ... by CritiTech, a Lawrence, Kan. drug development company. ...
... long encouraged by doctors as a supplement to support heart ... and colon cancer in mice in research led by Michigan ... Cancer Research . Jenifer Fenton, a food science and ... establishing a dose limit for docosahexaenoic acid (DHA), one of ...
Cached Biology News:Childrens Hospital LA discovers growth factor essential to epicardial cell function 2MU College of Veterinary Medicine to study efficacy of cancer drug in dogs 2Fish oil linked to increased risk of colon cancer in mice 2
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
WTAP Antibody...
Biology Products: